Trials / Completed
CompletedNCT04141228
A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US
Evaluation of Hospital Healthcare Utilization and Costs Among Hospitalized Venous Thromboembolism (VTE) Patients Treated With Apixaban or Warfarin in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28,000 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related hospital readmissions among hospitalized VTE patients treated with apixaban or warfarin, with or without low molecular weight heparin (LMWH)
Conditions
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2018-04-30
- Completion
- 2018-05-31
- First posted
- 2019-10-28
- Last updated
- 2019-10-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04141228. Inclusion in this directory is not an endorsement.